© AstraZeneca
We are excited to announce that AstraZeneca has become a Platinum Partner of EFCNI with the shared ambition to improve RSV care for preterm infants worldwide!
While most babies with RSV will only experience mild, cold-like symptoms and can be treated successfully in an outpatient setting, serious cases of RSV can have a significant impact and even be life-threatening.1 Especially infants born preterm, or with certain heart or lung problems, have a greater risk of getting more serious RSV infections.1
We are looking forward to working with AstraZeneca to raise awareness of the effects of this common seasonal virus amongst families, caregivers and healthcare professionals across the globe. Together, we will share educational messages and resources to help provide meaningful insights into how families can work to prevent RSV and appropriately care for their babies if they contract it.
We are delighted to begin our collaboration with AstraZeneca!
References:
1 Piedimonte G, Perez M. Respiratory Syncytial Virus Infection and Bronchiolitis. Pediatrics in Review (2014) 35:519-530.
